Eficácia de intervenção com enoxaparina baseada em sistema de pontuação nos desfechos perinatais de gestantes com trombofilias

Figueiró-Filho, Ernesto Antônio; Oliveira, Vanessa Marcon de; Breda, I.; Coelho, Lílian Rezende; Ferreira, Cristiane Munaretto

doi:10.1590/s0100-72032012001000005

Cited by 3 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis that studied couples who presented recurrent miscarriage showed an incidence of APS from 15% to 20% compared to approximately 5% in non-pregnant women without obstetric history 1 . After treatment, live birth rates among APS patients increase considerably 10 .…”

Section: Introductionmentioning

confidence: 99%

Antiphospholipid Syndrome

et al. 2019

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) was characterized as an autoimmune condition with the production of antiphospholipid antibodies (aPL) associated with thrombosis and morbidity in pregnancy. The prevalence of aPL in the population ranges from 1% to 5% in patients with APS. The hypotheses regarding pathophysiological mechanisms are strongly related to binding proteins and antiphospholipid antibodies. The exact mechanisms by which they lead to clinical manifestations appear to be heterogeneous, but it is believed which aPL contribute to the cellular activation/coagulation, and so cause the thrombotic events. The treatment of APS should be an individual character and several factors should be taken into accounts, such as a number of antibodies, the age of the patient and the history of thrombotic events.

show abstract

Section: Introductionmentioning

confidence: 99%

Antiphospholipid Syndrome

et al. 2019

View full text Add to dashboard Cite

show abstract

Safety and Efficacy of Low Molecular Weight Heparin Therapy During Pregnancy: Three Year Experience at a Tertiary Care Center

Singh

Varshney

Tripathi

et al. 2013

J Obstet Gynecol India

View full text Add to dashboard Cite

Purpose To evaluate safety and efficacy of low molecular weight heparin given for various indications during pregnancy. Methodology A detailed retrospective analysis of all the patients who received low molecular weight heparin (LMWH) for various indications over a period of 3 years (2010)(2011)(2012) at a tertiary care hospital in Northern India was performed. Results Fifty-five patients received LMWH over the period of 3 years, for various indications. Enoxaparin (1 mg/kg body weight OD/BD subcutaneously) was used. The indications were valvular heart disease with valve replacement, atrial fibrillation, or thrombus in 60 % patients; chronic deep vein thrombosis (DVT) in 7 % patients; thrombophilia in 9.1 % patients; recurrent pregnancy losses in 18 % patients; and DVT prophylaxis in 5.5 % patients. Abortion was seen in 7.2 % patients; fetal growth restriction in 10.9 % patients; and oligohydramnios, preeclampsia, gestational hypertension, placenta previa, abruptio placentae, and postpartum hemorrhage in 1.8 % patients. Stillbirth occurred in 3.6 % patients. No thromboembolic event was noted in any of the patients. None of the patients had any documented thrombocytopenia or clinical fracture. Conclusion Low molecular weight heparin can be used in pregnancy for various indications as an alternative to unfractionated heparin or warfarin as it is efficacious and safe.

show abstract

‘To test or not to test’, the arguments for and against thrombophilia testing in obstetrics

et al. 2017

View full text Add to dashboard Cite

Clinicians increasingly investigate women for thrombophilias due to their associations with venous thromboembolism and placenta-mediated pregnancy complication. These associations, however, are modest and based largely on retrospective data from studies with heterogeneous classifications and populations, leading to discordance between evidence and guidelines. Current evidence suggests a contributory rather than causative role for thrombophilia in placenta-mediated pregnancy complication and venous thromboembolism. With little evidence of benefit from antithrombotic therapy in placenta-mediated pregnancy complication, thrombophilia screening remains controversial. Given the low absolute risk of placenta-mediated pregnancy complication and gestational venous thromboembolism with heritable thrombophilia, universal screening is inappropriate. Selective screening for antiphospholipid syndrome is supported by robust evidence of benefit. Conversely, selective screening for heritable thrombophilia has not been shown to effectively manage placenta-mediated pregnancy complication. Therefore, at present heritable thrombophilia screening is not warranted for placenta-mediated pregnancy complication. Until we have better evidence from better stratified patient groups, caution should remain if we wish to practice evidence-based medicine.

show abstract

Eficácia de intervenção com enoxaparina baseada em sistema de pontuação nos desfechos perinatais de gestantes com trombofilias

Cited by 3 publications

References 32 publications

Antiphospholipid Syndrome

Antiphospholipid Syndrome

Safety and Efficacy of Low Molecular Weight Heparin Therapy During Pregnancy: Three Year Experience at a Tertiary Care Center

‘To test or not to test’, the arguments for and against thrombophilia testing in obstetrics

Contact Info

Product

Resources

About